Cincinnati Eye Institute, Southwest Ohio
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Cincinnati Eye Institute, Southwest Ohio sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Cincinnati Eye Institute, Southwest Ohio: 2 sponsored US clinical trials, 2 recruiting.
Cincinnati Eye Institute, Southwest Ohio sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Rhegmatogenous Retinal Detachment, with 1 trials.
Mid-pack sponsor footprint
Cincinnati Eye Institute, Southwest Ohio is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
NCT07695298
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
NCT06541574
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Cincinnati Eye Institute, Southwest Ohio pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Rhegmatogenous Retinal Detachment (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cincinnati Eye Institute, Southwest Ohio: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Cincinnati Eye Institute, Southwest Ohio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Cincinnati Eye Institute, Southwest Ohio page
2 registered trials is a research-attention snapshot, not an endorsement of Cincinnati Eye Institute, Southwest Ohio or any single study.
- 2 of Cincinnati Eye Institute, Southwest Ohio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Rhegmatogenous Retinal Detachment is the condition Cincinnati Eye Institute, Southwest Ohio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Rhegmatogenous Retinal Detachment trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cincinnati Eye Institute, Southwest Ohio pipeline card: 2 registered trials from official public datasets.Report a data error.